CA2411544A1 - N-alkyl-adamantyl triazinyl benzamide derivatives - Google Patents
N-alkyl-adamantyl triazinyl benzamide derivatives Download PDFInfo
- Publication number
- CA2411544A1 CA2411544A1 CA002411544A CA2411544A CA2411544A1 CA 2411544 A1 CA2411544 A1 CA 2411544A1 CA 002411544 A CA002411544 A CA 002411544A CA 2411544 A CA2411544 A CA 2411544A CA 2411544 A1 CA2411544 A1 CA 2411544A1
- Authority
- CA
- Canada
- Prior art keywords
- triazinyl
- adamantyl
- alkyl
- benzamide derivatives
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
-58- The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33689201P | 2001-11-12 | 2001-11-12 | |
US60/336,892 | 2001-11-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2411544A1 true CA2411544A1 (en) | 2003-05-12 |
CA2411544C CA2411544C (en) | 2008-10-07 |
Family
ID=23318138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002411544A Expired - Fee Related CA2411544C (en) | 2001-11-12 | 2002-11-08 | N-alkyl-adamantyl triazinyl benzamide derivatives |
Country Status (10)
Country | Link |
---|---|
US (1) | US6927219B2 (en) |
EP (1) | EP1310493B1 (en) |
JP (1) | JP4001542B2 (en) |
AT (1) | ATE302196T1 (en) |
BR (1) | BR0204588A (en) |
CA (1) | CA2411544C (en) |
DE (1) | DE60205564T2 (en) |
ES (1) | ES2244733T3 (en) |
MX (1) | MXPA02009783A (en) |
WO (1) | WO2003042190A1 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020182646A1 (en) * | 2001-04-30 | 2002-12-05 | Ke Huazhu | Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders |
PA8557501A1 (en) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS |
SE0200920D0 (en) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
PA8591801A1 (en) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | BENZAMID INHIBITORS OF THE P2X7 RECEIVER. |
SE0300480D0 (en) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
ATE371738T1 (en) * | 2003-04-17 | 2007-09-15 | Affectis Pharmaceuticals Ag | MEANS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AFFECTIVE DISORDERS |
JP4731468B2 (en) * | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | Benzamide inhibitor of P2X7 receptor |
EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
US20070032465A1 (en) * | 2003-05-29 | 2007-02-08 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha |
WO2004105796A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302192D0 (en) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
SE0302488D0 (en) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
ITMI20040255A1 (en) * | 2004-02-17 | 2004-05-17 | Univ Degli Studi Milano | ANTIANGIOGENIC ACTIVITY SUBSTANCES |
PL1725540T3 (en) * | 2004-03-05 | 2013-02-28 | Hoffmann La Roche | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
WO2005107804A1 (en) * | 2004-05-06 | 2005-11-17 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for respiratory ailment |
JP2008504363A (en) * | 2004-06-29 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Combination therapy using benzamide inhibitor of P2X7 receptor |
AU2005258924A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-`1,2,4!-triazin-2-YK!benzamide derivatives with P2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
AU2005258911A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
SA05260265A (en) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | Novel compounds |
WO2006035876A1 (en) * | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | Preventive and/or therapeutic medicine for rheumatoid arthritis |
SE0402925D0 (en) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
KR20080002790A (en) * | 2005-03-29 | 2008-01-04 | 코와 가부시키가이샤 | Preventive and/or therapeutic agent for rheumatoid arthritis |
WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
EP1906960A4 (en) * | 2005-07-11 | 2010-03-10 | Astrazeneca Ab | New combination 1 |
JP4850911B2 (en) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | Diaminopyrimidines as P2X3 and P2X2 / 3 modulators |
CA2619898C (en) * | 2005-09-01 | 2014-03-18 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
CN101300235B (en) | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
CN101296707A (en) * | 2005-10-28 | 2008-10-29 | 兴和株式会社 | Method for prevention and/or treatment of rheumatoid arthritis |
JPWO2008001499A1 (en) * | 2006-06-29 | 2009-11-26 | 興和株式会社 | Drugs for preventing and / or treating rheumatoid arthritis |
AR065806A1 (en) | 2007-03-22 | 2009-07-01 | Astrazeneca Ab | DERIVATIVES OF QUINOLINA, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF Rheumatoid ARTHRITIS. |
WO2009019503A2 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | P2x7 antagonists for use in the treatment of mood disorders |
CA2699631A1 (en) | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Pyridazinone compounds and p2x7 receptor inhibitors |
PE20091036A1 (en) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR |
WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
NZ587799A (en) | 2008-03-25 | 2012-06-29 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
ES2380908T3 (en) | 2009-04-14 | 2012-05-21 | Affectis Pharmaceuticals Ag | Novelty p2x7r antagonists and their use |
JP5562716B2 (en) * | 2010-05-12 | 2014-07-30 | 花王株式会社 | Voltage-gated cation channel inhibitor |
EP2569281A1 (en) | 2010-05-14 | 2013-03-20 | Affectis Pharmaceuticals AG | Novel methods for the preparation of p2x7r antagonists |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
TW201309706A (en) | 2011-07-22 | 2013-03-01 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
AU2013210682B2 (en) | 2012-01-20 | 2017-05-25 | Idorsia Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
WO2014091415A1 (en) | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
EP2935211B1 (en) | 2012-12-18 | 2016-11-09 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
CA2896790C (en) | 2013-01-22 | 2022-05-10 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
EP2956457B1 (en) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
CN103304498B (en) * | 2013-06-02 | 2015-03-04 | 张远强 | Anti-diabetic compound, as well as preparation method and application thereof |
CN103304500B (en) * | 2013-06-02 | 2015-03-04 | 张远强 | Novel anti-diabetic compound, as well as preparation method and application thereof |
JP6422164B2 (en) | 2013-12-26 | 2018-11-14 | 塩野義製薬株式会社 | Nitrogen-containing 6-membered ring derivatives and pharmaceutical compositions containing them |
CN104478859B (en) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | A kind of hydroxyadamantane tetrazotized zole compound, Preparation Method And The Use |
CN104478861B (en) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | A kind of nitro diamantane (obsolete) tetrazotized zole compound, Preparation Method And The Use |
CN104478860B (en) * | 2015-01-13 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | Diamantane (obsolete) tetrazole derivant, Preparation Method And The Use |
CN104496968A (en) * | 2015-01-13 | 2015-04-08 | 佛山市赛维斯医药科技有限公司 | Compound with halogen-substituted adamantane tetrazole structure and preparation method and application thereof |
CN104447704B (en) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | A kind of itrile group diamantane (obsolete) tetrazotized zole compound, Preparation Method And The Use |
CN104447703B (en) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | A kind of nitro diamantane (obsolete) tetrazotized zole compound, Preparation Method And The Use |
US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
US20180194769A1 (en) | 2015-07-06 | 2018-07-12 | Rodin Therapeutics, Inc. | Hetero-halo inhibitors of histone deacetylase |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
RU2753524C2 (en) | 2016-10-17 | 2021-08-17 | Сионоги Энд Ко., Лтд. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical compositions including them |
US10793567B2 (en) | 2017-01-11 | 2020-10-06 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
EP3664802B1 (en) | 2017-08-07 | 2022-02-23 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
KR102035463B1 (en) * | 2018-02-14 | 2019-11-26 | 연세대학교 산학협력단 | Pharmaceutical composition for treating cancer stem cells |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3789072A (en) * | 1970-04-22 | 1974-01-29 | Squibb & Sons Inc | Carboxamides |
EP0185731A4 (en) * | 1984-06-12 | 1988-11-02 | Fmc Corp | Herbicidal 2-aryl-1,2,4-triazine-3,5(2h,4h)-diones and sulfur analogs thereof. |
US4766233A (en) * | 1984-06-12 | 1988-08-23 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof |
US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US5128351A (en) * | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
KR930703259A (en) | 1990-12-17 | 1993-11-29 | 알베르투스 빌헬무스 요아네스 쩨스트라텐 | Disinfectant Isoquinoline Derivatives |
GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
US5686061A (en) | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
JP3144624B2 (en) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N-benzyldioxothiazolidylbenzamide derivative and method for producing the same |
JP3906935B2 (en) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N-substituted dioxothiazolidylbenzamide derivative and process for producing the same |
ATE267011T1 (en) | 1995-12-21 | 2004-06-15 | Bristol Myers Squibb Pharma Co | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE AS FACTOR XA INHIBITORS |
DE69706407T2 (en) * | 1996-03-29 | 2002-05-29 | Searle & Co | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTERGRIN ANTAGONISTS OR INHIBITORS |
CA2275796A1 (en) | 1996-12-23 | 1998-07-02 | Donald Joseph Phillip Pinto | Nitrogen containing heteroaromatics as factor xa inhibitors |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
DE19701287A1 (en) * | 1997-01-16 | 1998-07-23 | Wernicke & Co Gmbh | Process for increasing the service life of grinding wheels |
AU6753298A (en) | 1997-03-25 | 1998-10-20 | Astra Pharmaceuticals Limited | Novel pyridine derivatives and pharmaceutical compositions containing them |
WO1998043973A1 (en) | 1997-03-27 | 1998-10-08 | Novartis Ag | Intermediate products and method for the production of pyrimidine derivatives |
DE19719621A1 (en) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarboxylic acids |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
SE9704272D0 (en) * | 1997-11-21 | 1997-11-21 | Astra Pharma Prod | Novel Compounds |
SE9704546D0 (en) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (en) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704544D0 (en) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
JPH11318492A (en) * | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | Composition containing fluorogenic substrate |
US6320078B1 (en) | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
FR2783519B1 (en) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DE19851184A1 (en) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-arylsulfonylamino acid omega amides |
ES2249059T3 (en) | 1998-12-16 | 2006-03-16 | Bayer Healthcare Ag | NEW BIFENYL COMPOUNDS AND BIFENYL ANALOGS AS INTEGRINE ANTAGONIST |
KR100710091B1 (en) * | 1999-04-09 | 2007-04-25 | 아스트라제네카 아베 | Adamantane Derivatives |
JP2003500387A (en) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Factor Xa inhibitors |
SE9901875D0 (en) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
EP1088821A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
MXPA02005102A (en) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Retro anandamides, high affinity and stability cannabinoid receptor ligands. |
SE9904505D0 (en) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904652D0 (en) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
SE9904738D0 (en) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10005284A1 (en) | 2000-02-07 | 2001-08-09 | Bayer Ag | 1-Amino-3-phenyl-uracil preparation in high yield, for use as agrochemical or intermediate, by aminating 3-phenyl-uracil with 2-aminooxysulfonyl-1,3,5-trimethylbenzene |
GB0013737D0 (en) * | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
-
2002
- 2002-09-30 WO PCT/IB2002/004043 patent/WO2003042190A1/en not_active Application Discontinuation
- 2002-10-03 MX MXPA02009783A patent/MXPA02009783A/en active IP Right Grant
- 2002-11-07 EP EP02257719A patent/EP1310493B1/en not_active Expired - Lifetime
- 2002-11-07 AT AT02257719T patent/ATE302196T1/en not_active IP Right Cessation
- 2002-11-07 DE DE60205564T patent/DE60205564T2/en not_active Expired - Lifetime
- 2002-11-07 ES ES02257719T patent/ES2244733T3/en not_active Expired - Lifetime
- 2002-11-07 BR BR0204588-5A patent/BR0204588A/en not_active IP Right Cessation
- 2002-11-08 CA CA002411544A patent/CA2411544C/en not_active Expired - Fee Related
- 2002-11-12 US US10/292,886 patent/US6927219B2/en not_active Expired - Fee Related
- 2002-11-12 JP JP2002327661A patent/JP4001542B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1310493A1 (en) | 2003-05-14 |
DE60205564T2 (en) | 2006-06-01 |
ES2244733T3 (en) | 2005-12-16 |
DE60205564D1 (en) | 2005-09-22 |
JP2003183263A (en) | 2003-07-03 |
BR0204588A (en) | 2003-09-16 |
MXPA02009783A (en) | 2003-05-21 |
CA2411544C (en) | 2008-10-07 |
ATE302196T1 (en) | 2005-09-15 |
JP4001542B2 (en) | 2007-10-31 |
WO2003042190A1 (en) | 2003-05-22 |
US20030144293A1 (en) | 2003-07-31 |
US6927219B2 (en) | 2005-08-09 |
EP1310493B1 (en) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2411544A1 (en) | N-alkyl-adamantyl triazinyl benzamide derivatives | |
CA2466724A1 (en) | Benzamide and heteroarylamide as p2x7 receptor antagonists | |
EP3081214A3 (en) | Inhibitors of cellular necrosis | |
CA2525437A1 (en) | Benzamide inhibitors of the p2x7 receptor | |
WO2003044021A3 (en) | Substituted indolizine-like compounds and methods of use | |
IT1252868B (en) | ANTI-PHALALGIC PHARMACEUTICAL COMPOSITION FOR ENDONASAL ADMINISTRATION, PROCEDURE TO PREPARE IT AND ITS THERAPEUTIC USE | |
RU2325389C2 (en) | Composition and derivatives of substituted azaindoloxoacetapiperazine characterized by antiviral activity | |
BR0208150A (en) | Mch antagonists and their application in obesity treatment | |
CA2315827A1 (en) | Substituted pyridine and pyridazine compounds and their pharmaceutical use | |
EP1728863A3 (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency | |
CA2481723A1 (en) | 5ht2c receptor modulators | |
MY141984A (en) | Benzamide inhibitors of the p2x7 receptor | |
EP1251126A3 (en) | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | |
IL171914A0 (en) | Variants of il-18bp, their preparation and pharmaceutical compositions containing them | |
AP2000001947A0 (en) | Novel crystalline forms of an antiviral benzidazole compound. | |
WO1999009000A3 (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
CA2434009A1 (en) | Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy | |
RS20060662A (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
EP1736470A3 (en) | Pyrimidine derivatives as CB2 cannabinoid receptor modulators | |
BG106155A (en) | Novel derivatives and analogues of galanthamin | |
HK1048819A1 (en) | Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof | |
CA2385986A1 (en) | New use of modafinil and the d/l enantiomers for enhancing sexual function in mammals | |
ID28365A (en) | NEW NATURAL PRODUCTS DOWN | |
CA2003856A1 (en) | Therapeutic agent for renal disorders | |
WO2003018568A3 (en) | Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20151109 |